ReviewVaccines2020
Can Immunization of Hens Provide Oral-Based Therapeutics against COVID-19?
Review in Vaccines, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 31 citations in OpenAlex.
- Avian Antibodies as Potential Therapeutic Tools.Antibodies (Basel, Switzerland) · 2025Review
- Evaluating the Protective Role of Intranasally Administered Avian-Derived IgY Against SARS-CoV-2 in Syrian Hamster Models.Vaccines · 2024Article
- Comparison of immunoglobulin Y antibody production in new and spent laying hens.Veterinary world · 2024Article
- Evaluation of SARS-CoV-2-Specific IgY Antibodies: Production, Reactivity, and Neutralizing Capability against Virus Variants.International journal of molecular sciences · 2024Article
- Preparation of Bispecific IgY-scFvs Inhibition Adherences of EnterotoxigenicInternational journal of molecular sciences · 2024Article
- Monoclonal IgY antibodies: advancements and limitations for immunodiagnosis and immunotherapy applications.Therapeutic advances in vaccines and immunotherapy · 2024Review
- Article
- IgY Antibodies as Biotherapeutics in Biomedicine.Antibodies (Basel, Switzerland) · 2022Review
- SARS-CoV-2-specific immunoglobulin Y antibodies are protective in infected mice.PLoS pathogens · 2022Article
- Polyclonal hyper immunoglobulin: A proven treatment and prophylaxis platform for passive immunization to address existing and emerging diseases.Human vaccines & immunotherapeutics · 2022Review
- Exploring diet associations with Covid-19 and other diseases: a Network Analysis-based approach.Medical & biological engineering & computing · 2022Article
- Egg yolk immunoglobulin (IgY) targeting SARS-CoV-2 S1 as potential virus entry blocker.Journal of applied microbiology · 2022Article
- Specific anti-SARS-CoV-2 S1 IgY-scFv is a promising tool for recognition of the virus.AMB Express · 2022Article
- Preclinical Assessment of IgY Antibodies Against Recombinant SARS-CoV-2 RBD Protein for Prophylaxis and Post-Infection Treatment of COVID-19.Frontiers in immunology · 2022Article
- Antimicrobial Resistance in the COVID-19 Landscape: Is There an Opportunity for Anti-Infective Antibodies and Antimicrobial Peptides?Frontiers in immunology · 2022Review
- Recent advances in antibody-based immunotherapy strategies for COVID-19.Journal of cellular biochemistry · 2021Review
- IgY technology: Methods for developing and evaluating avian immunoglobulins for theWorld journal of methodology · 2021Review
- COVID-19 vaccines and nanomedicine.International journal of dermatology · 2021Review
- Inhalation monoclonal antibody therapy: a new way to treat and manage respiratory infections.Applied microbiology and biotechnology · 2021Review
- The preparation of N-IgY targeting SARS-CoV-2 and its immunomodulation to IFN-γ production in vitro.International immunopharmacology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
In the current worldwide pandemic situation caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and the newest coronavirus disease (COVID-19), therapeutics and prophylactics are urgently needed for a large population. Some of the prophylaxis strategies are based on the development of antibodies targeting viral proteins. IgY antibodies are a type of immunoglobulin present in birds, amphibians, and reptiles. They are usually obtained from egg yolk of hyper-immunized hens and represent a relatively inexpensive source of antibodies. Specific IgY can be produced by immunizing chickens with the target antigen and then purifying from the egg yolk. Chicken IgY has been widely explored as a clinical anti-infective material for prophylaxis, preventive medicine, and therapy of infectious diseases. Administered non-systemically, IgY antibodies are safe and effective drugs. Moreover, passive immunization with avian antibodies could become an effective alternative therapy, as these can be obtained relatively simply, cost-efficiently, and produced on a large scale. Here, we highlight the potential use of polyclonal avian IgY antibodies as an oral prophylactic treatment for respiratory viral diseases, such as COVID-19, for which no vaccine is yet available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.